01 4Viibryd/Fetzima
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 336
2016 Revenue in Millions : 342
Growth (%) : -2
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 350
2017 Revenue in Millions : 336
Growth (%) : 4%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 342
2015 Revenue in Millions : 328
Growth (%) : 4
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 424
2018 Revenue in Millions : 350
Growth (%) : 21
LOOKING FOR A SUPPLIER?